Aro Biotherapeutics is a preclinical stage biotechnology company focused on discovery and development of Centyrins, a new class of small, structurally simple, ultra-stable and highly soluble proteins engineered to specifically bind antigens with high affinity. Aro is building a proprietary pipeline in Oncology and Immunology, while establishing risk-shared partnerships in these and other disease areas.

    Co-founded in January 2018 by Aro President and CEO, Sue Dillon, PhD and Aro CSO, Karyn O’Neil, PhD, both former R&D leaders at the Janssen Pharmaceutical Companies of Johnson & Johnson, Aro has recruited a highly accomplished scientific and executive management team headquartered at the new Biolabs@CIC incubator in University City, Philadelphia.